Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference.
The virtual event will take place on September 30, 2025, featuring a webcast presentation at 2:00 p.m. ET. Management will also be available for one-on-one meetings with investors throughout the conference. The company develops products for various applications including wound care, eye care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (Nasdaq:SNOA), una società sanitaria specializzata in tecnologia Microcyn® basata su acido ipocloroso stabilizzato (HOCl) prodotti, ha annunciato la sua partecipazione al prossimo Lytham Partners Fall 2025 Investor Conference.
L'evento virtuale si svolgerà 30 settembre 2025, con una presentazione in webcast alle 14:00 ET. La direzione sarà disponibile anche per incontri individuali con gli investitori durante la conferenza. L'azienda sviluppa prodotti per diverse applicazioni tra cui cura delle ferite, cura degli occhi, condizioni dermatologiche, podologia e salute animale.
Sonoma Pharmaceuticals (Nasdaq:SNOA), una empresa de atención sanitaria especializada en la tecnología Microcyn® basada en ácido hipocloroso estabilizado (HOCl) para productos, ha anunciado su participación en la próxima Lytham Partners Fall 2025 Investor Conference.
El evento virtual se llevará a cabo el 30 de septiembre de 2025, con una presentación en webcast a las 2:00 p.m. ET. La dirección también estará disponible para reuniones uno a uno con los inversores durante la conferencia. La empresa desarrolla productos para diversas aplicaciones, incluyendo cuidado de heridas, cuidado ocular, condiciones dermatológicas, podología y salud animal.
소노마 파마솔루틱스(Sonoma Pharmaceuticals, Nasdaq:SNOA)는 Microcyn® 기술 기반의 안정화된 차아염소산 HOCl 제품을 전문으로 하는 헬스케어 회사로, 다가오는 Lytham Partners Fall 2025 Investor Conference에 참여한다고 발표했습니다.
가상 행사는 2025년 9월 30일에 열리며, 웹캐스트 발표가 오후 2시 동부표준시(ET)에 진행됩니다. 경영진은 컨퍼런스 기간 동안 투자자와의 1:1 미팅도 가능합니다. 이 회사는 상처 관리, 안과 관리, 피부 질환, 발 관리 및 동물 건강 관리 등 다양한 용도의 제품을 개발합니다.
Sonoma Pharmaceuticals (Nasdaq:SNOA), une société de soins de santé spécialisée dans la technologie Microcyn® basée sur de l'acide hypochloreux stabilisé (HOCl), a annoncé sa participation à la prochaine Conference investisseurs Lytham Partners Fall 2025.
L'événement virtuel aura lieu le 30 septembre 2025, avec une présentation en webcast à 14h00 ET. La direction sera également disponible pour des réunions individuelles avec les investisseurs pendant la conférence. La société développe des produits pour diverses applications, notamment les soins des plaies, les soins oculaires, les affections dermatologiques, la podologie et la santé animale.
Sonoma Pharmaceuticals (Nasdaq:SNOA), ein Gesundheitsunternehmen, das sich auf die Microcyn®-Technologie basierte Produkte mit stabilisiertem Hypochlorousäure (HOCl) spezialisiert hat, hat seine Teilnahme an der bevorstehenden Lytham Partners Fall 2025 Investor Conference angekündigt.
Die virtuelle Veranstaltung findet am 30. September 2025 statt und beinhaltet eine Webcast-Präsentation um 14:00 Uhr ET. Das Management wird auch während der Konferenz für Einzelgespräche mit Investoren zur Verfügung stehen. Das Unternehmen entwickelt Produkte für verschiedene Anwendungen, darunter Wundversorgung, Augenpflege, dermatologische Erkrankungen, Podologie und Tiergesundheit.
سونوما للأدوية (ناسداك:SNOA)، شركة رعاية صحية متخصصة في تقنيات Microcyn® القائمة على حمض الهبوكلورُوز Stabilized HOCl، أعلنت عن مشاركتها في مؤتمر المستثمرين خريف 2025 لشركة ليثم بارتنرز القادم.
سيعقد الحدث الافتراضي في 30 سبتمبر 2025، مع عرض ويب في 2:00 مساءً بتوقيت شرق الولايات المتحدة. كما سيكون بالإدارة متاحًا لعقد اجتماعات فردية مع المستثمرين طوال فترة المؤتمر. تشDevelop الشركة منتجات لمجموعة تطبيقات تشمل رعاية الجروح، رعاية العين، الحالات الجلدية، طب الأقدام ورعاية صحة الحيوان.
Sonoma Pharmaceuticals (Nasdaq:SNOA)，一家专注于基于 Microcyn® 技术的稳定化次氯酸 HOCl 产品 的医疗保健公司，已宣布将参加即将举行的 Lytham Partners Fall 2025 Investor Conference。
此次虚拟活动将于 2025年9月30日 举行，预计在 美国东部时间下午2:00进行网络直播演示。管理层也将于整个会议期间与投资者进行一对一会谈。该公司开发用于创伤护理、眼护、皮肤科状况、足病科以及动物健康护理等多种应用的产品。
- None.
- None.
BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.
Company Webcast
The webcast presentation will take place at 2:00 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/or directly at https://app.webinar.net/A3L8zpab2q9. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Sonoma Pharmaceuticals (SNOA) presenting at the Lytham Partners Fall 2025 Conference?
How can investors access Sonoma Pharmaceuticals' (SNOA) Lytham Partners conference presentation?
How can investors schedule one-on-one meetings with Sonoma Pharmaceuticals (SNOA) management?
What products does Sonoma Pharmaceuticals (SNOA) develop?
